NorthCrest Asset Manangement LLC Has $24.56 Million Stock Position in Bristol Myers Squibb Company $BMY

NorthCrest Asset Manangement LLC boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 462,833 shares of the biopharmaceutical company’s stock after acquiring an additional 36,677 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in Bristol Myers Squibb were worth $24,558,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. CVA Family Office LLC lifted its position in shares of Bristol Myers Squibb by 2.6% during the third quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 223 shares in the last quarter. MSH Capital Advisors LLC increased its holdings in shares of Bristol Myers Squibb by 2.9% in the third quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company’s stock valued at $362,000 after purchasing an additional 223 shares in the last quarter. Bell & Brown Wealth Advisors LLC raised its position in Bristol Myers Squibb by 0.5% in the 3rd quarter. Bell & Brown Wealth Advisors LLC now owns 42,691 shares of the biopharmaceutical company’s stock worth $1,925,000 after purchasing an additional 224 shares during the last quarter. Harbor Investment Advisory LLC raised its position in Bristol Myers Squibb by 2.5% in the 4th quarter. Harbor Investment Advisory LLC now owns 9,322 shares of the biopharmaceutical company’s stock worth $503,000 after purchasing an additional 224 shares during the last quarter. Finally, Addison Advisors LLC lifted its holdings in Bristol Myers Squibb by 6.2% during the 3rd quarter. Addison Advisors LLC now owns 3,972 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 232 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. and EMA approvals expanded Opdivo’s use into frontline Stage III/IV classical Hodgkin’s lymphoma for patients 12+, strengthening BMY’s oncology franchise and near‑term revenue potential. Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo US FDA approves Bristol Myers Squibb’s cancer drug for Hodgkin’s lymphoma
• Positive Sentiment: Sotyktu (BMY) received a label expansion into psoriatic arthritis, broadening BMY’s immunology franchise and helping offset pressure from legacy oncology and cardiovascular patent cliffs. Will the Recent Label Expansion of BMY’s Sotyktu Boost Its Prospects?
• Positive Sentiment: BMY advanced its protein‑degradation program: first‑in‑human dosing of BMS‑986506 for clear cell renal cell carcinoma triggered a $10M milestone to Evotec, signaling pipeline progress and potential long‑term upside if early data read out well. Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration
• Neutral Sentiment: HSBC nudged its price target to $60, a modest analyst upgrade that signals some confidence but is unlikely to drive large near‑term moves on its own. HSBC Boosts Bristol Myers Squibb (NYSE:BMY) Price Target to $60.00
• Neutral Sentiment: BMY scheduled Q1 2026 results for April 30 — a near‑term event that could reprice the stock depending on revenue and EPS versus guidance/expectations. Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
• Neutral Sentiment: Coverage pieces (Schaeffer, Zacks) have highlighted BMY as a recommended pick or trending ticker, which can lift interest but may already be priced in. Top Stock Picks of 2026: Bristol-Myers Squibb Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
• Negative Sentiment: Technical weakness flagged by a potential “death cross” (50‑day moving average crossing below 200‑day) can prompt selling by trend‑followers and contributed to the down‑pressure. These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on BMY shares. Leerink Partners lifted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target on the stock. The Goldman Sachs Group reiterated a “neutral” rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Citigroup boosted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Finally, Guggenheim restated a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $61.41.

Bristol Myers Squibb Stock Down 1.2%

Bristol Myers Squibb stock opened at $57.42 on Friday. The firm has a market capitalization of $116.93 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 0.16 and a beta of 0.26. The company’s 50 day simple moving average is $58.60 and its 200 day simple moving average is $51.84. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.